Prosecution Insights
Last updated: April 19, 2026

Examiner: JUSTICE, GINA CHIEUN YU

Tech Center 1600 • Art Units: 1611 1617 1627

This examiner grants 55% of resolved cases

Performance Statistics

55.1%
Allow Rate
-4.9% vs TC avg
992
Total Applications
+8.2%
Interview Lift
1218
Avg Prosecution Days
Based on 944 resolved cases, 2023–2026

Rejection Statute Breakdown

0.9%
§101 Eligibility
15.5%
§102 Novelty
43.9%
§103 Obviousness
20.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18244798 Dermatological Product Final Rejection SYMRISE AG
18558415 ALPELISIB FORMULATION Non-Final OA Novartis AG
19178329 ODOR CONTROL COMPOSITION CONCENTRATES Final Rejection MICROBAN PRODUCTS COMPANY
18287145 COMPOSITION COMPRISING AT LEAST ONE SILICONE OF FORMULA (I), AT LEAST ONE SILICONE OF FORMULA (II) AND AT LEAST ONE COLORING AGENT Non-Final OA L'OREAL
18362528 EMULSION COMPOSITIONS CONTAINING CARBOSILOXANE DENDRIMER COMPOUND AND AQUEOUS PHASE FILM FORMER Non-Final OA L'OREAL
17769413 NEMATOSTATIC COMPOSITIONS, AND USE THEREOF IN AGRICULTURE Non-Final OA AGRO INNOVATION INTERNATIONAL
18623605 Sulfate-Free Personal Care Compositions and Methods for Preventing and Treating Pollution Damage to Skin Final Rejection Colgate-Palmolive Company
18462474 HAIR REPAIR COMPOSITION Non-Final OA RHODIA OPERATIONS
18745158 TOPICAL MUSCLE RELAXATION COMPOSITIONS AND METHODS Non-Final OA MARY KAY INC.
17771169 AGROCHEMICAL COMPOSITION FOR SOIL TREATMENT AND PEST CONTROL METHOD USING SAME Non-Final OA KUMIAI CHEMICAL INDUSTRY CO., LTD.
18293272 MAGNESIUM OXIDE-CONTAINING PHARMACEUTICAL COMPOSITION FOR TREATING PEDIATRIC CHRONIC FUNCTIONAL CONSTIPATION Non-Final OA SETOLAS Holdings, Inc.
17689844 COMPOSITIONS FOR ORAL MICROADHESIVE DOSAGE FORMS Final Rejection FP NUTRACEUTICALS, LLC
18228280 COMPOSITIONS AND METHODS FOR IMPROVING SOIL CONDITION Non-Final OA Kannar Earth Science, Ltd.
18272163 TOPICAL COMPOSITION Non-Final OA LILIGER LTD.
18259832 NEW COMBINATIONS AND COMPOSITIONS OF SUCRALFATE IN ALGINATE AND THEIR USE IN THERAPY Non-Final OA NYUMA PHARMA SRL
17416049 NOVEL COSMETIC AND DERMATOLOGICAL USES OF AN EXTRACT OF CISTUS MONSPELIENSIS Non-Final OA BASF Beauty Care Solutions France SAS
18195761 Bag System Containing a Nutrient Composition Comprising Whole Food Sole Source Meal Non-Final OA Kate Farms, Inc.
18008012 FOOD SUPPLEMENT AND FOOD Final Rejection PM-International AG
18000567 EXTRACTION TECHNIQUES TO PRESERVE CANNABINOID AND TERPENOID PROFILES Non-Final OA CReDO Science, LLC
18008167 ANTI-MICROBIAL AND ANTI-INFLAMMATORY COMPOSITION COMPRISING ARTHROSPIRA EXTRACTS AND AN ORGANIC ACID Non-Final OA BIOVITE AUSTRALIA PTY LTD
17784851 METHOD WHICH BRINGS BENEFITS TO HEALTH AND/OR GROWTH OF USEFUL PLANTS Non-Final OA ISHIHARA SANGYO KAISHA, LTD.
17927801 A Composition for Management of COVID-19 and Associated Disorders Non-Final OA Vedicinals India Private Limited
17922748 TOPICAL FORMULATIONS COMPRISING DUTASTERIDE FOR TREATING DERMATOLOGICAL DISORDERS INCLUDING MALE PATTERN BALDNESS Non-Final OA XYON Health Inc.
17995664 COMPOSITION FOR HAIR IMPROVEMENT Non-Final OA Dr. Cherry Inc.
17912424 PHARMACEUTICAL COMPOSITION OF EXTENDED-RELEASE ORAL SUSPENSION AND PROCESS FOR PREPARATION THEREOF Final Rejection NOKHA TRADING LLP
17800570 BREAKABLE GALENIC CAPSULE Final Rejection Fingerclik, S.L.
17783399 PLANT STOMATA OPENING PROMOTING AGENT Non-Final OA OAT Agrio Co., Ltd.
17626888 SYNERGISTIC COMBINATION OF S-KETOROLAC AND PREGABALIN IN A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NEUROPATHIC PAIN Final Rejection Carlos Amezcua Amezcua

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month